{
    "clinical_study": {
        "@rank": "139587", 
        "arm_group": [
            {
                "arm_group_label": "Infant formula", 
                "arm_group_type": "Active Comparator", 
                "description": "HA formula + starch + L. reuteri"
            }, 
            {
                "arm_group_label": "Standard Formula", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Standard Infant Formula"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to show that an hypoallergenic infant starter formula\n      containing starch and the probiotic L. reuteri decreases the severity of\n      regurgitation/spitting-up in infants presenting regurgitation/spitting-up , and who have\n      taken it for 4 weeks, in comparison with a standard infant starter formula."
        }, 
        "brief_title": "Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Regurgitation, Gastric", 
        "condition_browse": {
            "mesh_term": "Regurgitation, Gastric"
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this trial is to show that the test formula (HA formula + starch +\n      L. reuteri) decreases the severity (frequency + volume) of regurgitation/spitting-up in\n      infants and ultrasound gastric emptying time, compared to a classical infant starter\n      formula."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Full term infant (37 weeks \u2264 gestation \u2264 42 weeks)\n\n          -  Age of infant between 5 days and 5 months\n\n          -  NGA\n\n          -  Infant exclusively formula-fed at enrollment\n\n          -  Presenting regurgitation/spitting-up according to the parents' perception\n\n          -  Vandenplas score of at least 2 and maximum 5\n\n          -  Having obtained the subject's legal representative's written informed consent\n\n        Exclusion Criteria:\n\n          -  Previous antireflux treatment\n\n          -  Previous consumption of AR infant formula or external thickener\n\n          -  Previous consumption of a formula with L. reuteri\n\n          -  Cow's milk allergy symptoms according to medical decision\n\n          -  Congenital illness or malformation that may affect growth\n\n          -  Significant pre-natal and/or post-natal disease\n\n          -  Newborn whose parents / caregivers cannot be expected to comply with study procedures\n\n          -  Newborn currently participating or having participated in another clinical trial\n             during the last 4 weeks prior to the beginning of this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "5 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956682", 
            "org_study_id": "University of Bari"
        }, 
        "intervention": {
            "arm_group_label": "Infant formula", 
            "intervention_name": "HA formula + starch + L. reuteri", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bari", 
                    "country": "Italy", 
                    "state": "BA", 
                    "zip": "70100"
                }, 
                "name": "Ospedale Pediatrico Giovanni XXIII"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying", 
        "overall_contact": {
            "email": "f.indrio@alice.it", 
            "last_name": "Flavia Indrio, MD"
        }, 
        "overall_official": {
            "affiliation": "University of Bari", 
            "last_name": "Flavia Indrio, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is the difference in the proportions of improved subjects at four weeks of treatment between the treatment and control groups.", 
            "measure": "Regurgitation", 
            "safety_issue": "No", 
            "time_frame": "four weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956682"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Bari", 
            "investigator_full_name": "Flavia Indrio", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess whether the groups have comparable growth", 
                "measure": "Growth", 
                "safety_issue": "No", 
                "time_frame": "Four weeks of treatment"
            }, 
            {
                "description": "To assess the severity of regurgitation/spitting-up To assess the frequency of regurgitation/spitting-up To assess the volume of regurgitation/spitting-up", 
                "measure": "Regurgitation score", 
                "safety_issue": "No", 
                "time_frame": "Four weeks treatment"
            }, 
            {
                "description": "To compare the ultrasound gastric empty rate", 
                "measure": "Gastric empty rate", 
                "safety_issue": "No", 
                "time_frame": "Four week treatment"
            }, 
            {
                "description": "To assess the infants' digestive tolerance", 
                "measure": "Digestive tolerance", 
                "safety_issue": "No", 
                "time_frame": "Four weeks treatment"
            }, 
            {
                "description": "To assess stool frequency", 
                "measure": "Stool frequency", 
                "safety_issue": "No", 
                "time_frame": "Four weeks treatment"
            }, 
            {
                "description": "To assess the subject's compliance to product consumption.", 
                "measure": "compliance", 
                "safety_issue": "No", 
                "time_frame": "four weeks intervention"
            }, 
            {
                "description": "To measure family financial and non-financial burden related with the regurgitation", 
                "measure": "Financial and non-financial burden", 
                "safety_issue": "No", 
                "time_frame": "Four week treatment"
            }
        ], 
        "source": "University of Bari", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Bari", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}